NCT03294798View on ClinicalTrials.gov

Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 13, 2017

Primary Completion Date

March 15, 2019

Study Completion Date

March 15, 2021

Conditions
Hepatitis B Virus
Interventions
BIOLOGICAL

Human Serum Albumin/interferon alpha2b fusion protein

In experiemental groups, each subject will recieve 600,750,900mg once per two weeks during multiple dose period.

BIOLOGICAL

Pegasys

In comparator group, each subject will recieve 180mcg once per week.

Trial Locations (1)

100069

Beijing YouAn Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Tianjin SinoBiotech Ltd.

INDUSTRY

NCT03294798 - Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient | Biotech Hunter | Biotech Hunter